Champions Oncology (CSBR) Common Equity (2011 - 2026)

Champions Oncology has reported Common Equity for 16 years, with the latest figure at $4.1 million in Q2 2026.

• On a quarterly basis, Common Equity rose 7.85% year-over-year to $4.1 million in Q2 2026; TTM through Apr 2026 was $4.1 million, a 7.85% increase from a year earlier, with the FY2026 full-year figure at $4.1 million, up 7.85% from the prior year.
• Common Equity was $4.1 million for Q2 2026 at Champions Oncology, down from $4.4 million in the prior quarter.
• The five-year high for Common Equity was $9.2 million in Q1 2022, with the low at -$2.1 million in Q1 2024.
• Average Common Equity over 5 years is $4.0 million, with a median of $4.1 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 141.05% in 2024, then surged 1165.66% in 2025.
• Over 5 years, Common Equity stood at $9.2 million in 2022, then slumped by 98.99% to $93000.0 in 2023, then soared by 632.26% to $681000.0 in 2024, then jumped by 521.29% to $4.2 million in 2025, then dropped by 3.85% to $4.1 million in 2026.
• The last three Common Equity figures came in at $4.1 million (Q2 2026), $4.4 million (Q1 2026), and $4.2 million (Q4 2025), per Business Quant data.